Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341 · see citing works

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257 · see citing works

Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)

Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,088 · see citing works

Src family kinases, key regulators of signal transduction

Parsons, S. J., & Parsons, J. T. (2004) · Oncogene · doi:10.1038/sj.onc.1208160 · Cited by 942 · see citing works

Differentiation Stage-Specific Inhibition of the Raf-MEK-ERK Pathway by Akt

Rommel, C., Clarke, B. A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., & Glass, D. J. (1999) · Science · doi:10.1126/science.286.5445.1738 · Cited by 759 · see citing works

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661 · see citing works

c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function

Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649 · see citing works

c-Src and cooperating partners in human cancer

Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · see citing works

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria‐Petit, A., Crombet, T., Jothy, S., Hicklin, D. J., Böhlen, P., Schlaeppi, J.-M., Rak, J. W., & Kerbel, R. S. (2001) · PubMed · Cited by 558 · see citing works

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1415 · Cited by 472 · see citing works

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

Fan, Z., Baselga, J., Masui, H., et al. (1993) · PubMed · Cited by 431 · see citing works

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

Wu, X., Fan, Z., Masui, H., Rosen, N. X., & Mendelsohn, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381 · see citing works

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 379 · see citing works

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347 · see citing works

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

Ciardiello, F., Bianco, R., Damiano, V., Lorenzo, S. D., Pepe, S., Placido, S. D., Fan, Z., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (1999) · PubMed · Cited by 332 · see citing works

A tail of two src's: Mutatis mutandis

Hunter, T. R. (1987) · Cell · doi:10.1016/0092-8674(87)90745-8 · Cited by 282 · see citing works

Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function.

Soderquist, A. M., & Carpenter, G. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90787-8 · Cited by 233 · see citing works

Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.

Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228 · see citing works

RING Finger Mutations that Abolish c-Cbl-Directed Polyubiquitination and Downregulation of the EGF Receptor Are Insufficient for Cell Transformation

Thien, C. B. F., Walker, F., & Langdon, W. Y. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00183-6 · Cited by 177 · see citing works

c-SRC Phosphorylates Epidermal Growth Factor Receptor on Tyrosine 845

Sato, K., Sato, A., Aoto, M., & Fukami, Y. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2574 · Cited by 139 · see citing works

Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors

Bao, J., Gur, G., & Yarden, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437945100 · Cited by 136 · see citing works

True

Liu, B., Fang, M., Schmidt, M., Lü, Y., Mendelsohn, J. M., & Fan, Z. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1201 · Cited by 125 · see citing works

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody

Liu, B., Fang, M., Lü, Y., Mendelsohn, J. M., & Fan, Z. (2001) · Oncogene · doi:10.1038/sj.onc.1204277 · Cited by 105 · see citing works

Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis

Boerner, J. L., Biscardi, J. S., Silva, C. M., & Parsons, S. J. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20138 · Cited by 74 · see citing works

Src‐dependent phosphorylation of the EGF receptor Tyr‐845 mediates Stat‐p21waf1 pathway in A431 cells

Sato, K., Nagao, T., Iwasaki, T., Nishihira, Y., & Fukami, Y. (2003) · Genes to Cells · doi:10.1046/j.1356-9597.2003.00691.x · Cited by 73 · see citing works

Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

Steck, P. A., Lee, P., Hung, M., et al. (1988) · PubMed · Cited by 66 · see citing works

The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway

Liu, B., & Fan, Z. (2001) · Oncogene · doi:10.1038/sj.onc.1204490 · Cited by 41 · see citing works

Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function

Ciesielski, M. J., & Fenstermaker, R. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203409 · Cited by 40 · see citing works

Deletion and tandem duplication of exons 2–7 in the epidermal growth factor receptor gene of a human malignant glioma

Fenstermaker, R. A., & Ciesielski, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203802 · Cited by 26 · see citing works

Characterization of a Novel Epidermal‐Growth‐Factor‐Receptor‐Related 200‐kDa Tyrosine Kinase in Tumor Cells

Panneerselvam, K., Kanakaraj, P., Raj, S., et al. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0951g.x · Cited by 12 · see citing works

Characterization of a Novel Epidermal-Growth-Factor-Receptor-Related 200-kDa Tyrosine Kinase in Tumor Cells

Panneerselvam, K., Kanakaraj, P., Raj, S., et al. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20641.x · Cited by 11 · see citing works

New drug to treat most common lung cancer.

(2005) · PubMed · Cited by 2 · see citing works

Speedy Approvals for New Cancer Treatments

(2003) · PsycEXTRA Dataset · doi:10.1037/e542942006-008 · Cited by 1 · see citing works

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · see citing works

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · see citing works

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473 · see citing works

The Role of Src in Solid Tumors

Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346 · see citing works

The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1α and Bcl-2 and Activating the Beclin 1/hVps34 Complex

Li, X., & Fan, Z. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0157 · Cited by 179 · see citing works

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160 · see citing works

Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology &amp; Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157 · see citing works

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87 · see citing works

Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer

Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79 · see citing works

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67 · see citing works

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in <i>KRAS</i> wild‐type tumor cells

Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., Queralt, B., Báez, L., Guardeño, R., Hernández‐Yagüe, X., Martin‐Castillo, B., Brunet, J., & Menendez, J. A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22952 · Cited by 47 · see citing works

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer

Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L. (2018) · Oncogene · doi:10.1038/s41388-018-0289-x · Cited by 33 · see citing works

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib

Bozec, A., Formento, P., Fischel, J., et al. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2009.11.010 · Cited by 4 · see citing works

Intracellular Signaling Mechanisms of Resistance to EGFR-Targeting Agents

Quesnelle, K. M. (2012) · D-Scholarship@Pitt (University of Pittsburgh)

SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models

Napolitano, S., Belli, V., Castellone, M. D., Parascandolo, A., Martinelli, E., Martini, G., Cardone, C., Morgillo, F., Orditura, M., Ciardiello, F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw362.09

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines

Boeckx, C., den Bossche, J. V., Pauw, I. D., Peeters, M., Lardon, F., Baay, M. F. D., & Wouters, A. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1197-6 · Cited by 26 · see citing works

Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes

Hu, Y., Dong, X., Liu, X., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00927 · Cited by 22 · see citing works